Incyte Corp (INCY-Q) Profile - The Globe and Mail

Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

Key Executives

Name	Title
Pablo J. Cagnoni	Other Corporate Officer/President, Divisional
William Meury	CEO/Director/President
Steven H. Stein	Executive VP/Chief Medical Officer
Michael James Morrissey	Executive VP/Other Corporate Officer
Thomas Tray	CFO/Chief Accounting Officer/Vice President
Matteo Trotta	Executive VP/General Manager, Geographical
Lee Heeson	Executive VP, Subsidiary
Mohamed Khairie Issa	Executive VP/Other Corporate Officer
David H. Gardner	Chief Strategy Officer/Executive VP
Richard A. Hoffman	Executive VP/General Counsel
Soni Basi	Executive VP/Other Executive Officer